SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote ()3/18/2000 12:31:00 AM
From: Doc Bones  Read Replies (1) of 52153
 
Herewith two recent commentaries on that mainstay of stock valuation, the analyst. Both are from the (computer) tech world, but their message is universal.

Adam Lashinsky is easily my favorite writer at The Street.com. I think he's sharp, independent, and reform-minded.

Doc

____________________

thestreet.com


Commentary : SiliconStreet.com


Research Doesn't Always Sell

By Adam Lashinsky
Silicon Valley Columnist
3/17/00 7:00 AM ET


NEW YORK -- Scott Sipprelle, once a big-time investment banker with Morgan Stanley, has learned at least one lesson in the two years since he set up his own firm, Midtown Research Group: Research doesn't sell.

This realization is of more than passing interest to students of the brokerage world who are trying to understand why the Chinese Wall has ceased to separate investment bankers from their research analysts. In other words, Wall Street research essentially is a prop for banking, the latter being far more remunerative than the former.
<snip>
Most revealing are Sipprelle's observations about the IPO roadshow. Fund managers who attend scores of meetings don't have time to absorb each story. Sometimes, he notes acerbically, all they carry away is an impression: That the room was crowded, say. "A good roadshow never has enough seats," he says -- dead seriously.
<snip>
_____________________________

Charles H. Ferguson has written an excellent tell-all (not to mention get-even) about founding an Internet startup, eventually selling it to Microsoft, where its product became "Front Page". The book has received good reviews. Besides a strong tech/management background, Ferguson has a Ph.D. from MIT in political science, and has done heavy government and industry consulting.

----------

Charles H. Ferguson

High Stakes, No Prisoners

Times Business - Random House 1999

--------

THE ANALYSTS, p. 131

Any remaining illusions I harbored about the workings of my industry were dispelled by our meetings with analysts, market research firms, and industry newsletters...

You always see gushing analyst white papers as part of the press package when a new product comes out. We needed one too. Well, it turns out that you buy them. We negotiated with several firms. Aberdeen wanted $16,000, preferably in stock, but Seybold would do it for $15,000 in cash. So we used Seybold, who sent us a nice man who wrote exactly what we told him to. I didn't like it, but everyone made it very clear that this was standard practice, that it was necessary for us, and that I should keep my mouth shut and stay out of the way. So I did.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext